The Fully Human Anti-Cd47 Antibody Srf231 Has Dual-Mechanism Antitumor Activity Against Chromic Lymphocytic Leukemia (Cll) Cells And Increases The Activity Of Both Rituximab And Venetoclax
BLOOD（2018）
摘要
Background
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要